Investment Rating - The report maintains a "Buy" rating for the company [8] Core Views - The logic behind increasing equity allocation and scale growth has been validated, with a positive outlook for the asset side in the short term and potential revaluation of industry profitability and valuation in the medium to long term. The company is continuously advancing channel reforms, emphasizing supply-side innovation, and deepening its involvement in healthcare and comprehensive financial services, which are expected to help build future product and pricing barriers [2][12] Summary by Sections Financial Performance - The company reported a net profit attributable to shareholders of 68.05 billion yuan, a year-on-year decline of 8.8%. The new business value reached 22.34 billion yuan, showing a comparable year-on-year growth of 39.8% [6][12] New Business Value - The new business value growth was primarily driven by an improvement in the new business value rate, which increased from 17.3% to 26.1% on a comparable basis. The new single premium decreased by 7.2% to 85.57 billion yuan [12] Distribution Channels - The individual insurance agent count decreased by 6.3% to 340,000, likely due to a 17.3% decline in agent income. However, the per capita new business value improved by 21.6%. The bank insurance channel's new business value grew by 168.6%, with new single premiums increasing by 77.6% [12] Property and Casualty Insurance - The company achieved a property and casualty insurance premium of 171.86 billion yuan, a year-on-year increase of 7.1%. The auto insurance premium was 108.61 billion yuan, up 3.6%, while the new energy vehicle insurance premium reached 21.7 billion yuan, growing by 46.2% [12] Asset Allocation - The equity allocation increased from 7.6% in 2024 to 10.5%, while the bond exposure decreased from 61.7% to 60.8%. The real estate exposure was reduced from 3.5% to 3.3% [12] Valuation - The current PEV valuation for 2025 is 0.68 times, indicating significant room for recovery [2][12]